ASBP
Aspire Biopharma Holdings, Inc.Company Information
- Company Name
- Aspire Biopharma Holdings, Inc.
- CIK
- CIK0001847345
- Category
- <br>Emerging growth company
- Ticker: Exchange
- ASBP: Nasdaq, ASBPW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ASBP
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-05
- Last sale
- 2023-08-18
- Shares purchased (TTM)
- 10,500
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,946
- Shares outstanding
- 1,037,874
- Ownership
- 4.52%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 24.75%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | - | 6 | 1 | 2 | 0 | 1 | 0 | - | - | 0 | - | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 12 | 6 | - | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 13 | 7 | 1 | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Other Receivables | - | - | - | - | - | - | 0 | 0 | 0 | - | - | - | ||||||
| Deferred Finance Costs Net | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 14 | 7 | 1 | 2 | 1 | 2 | 0 | 7 | 7 | 20 | 20 | 20 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Other Liabilities Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | - | - | - | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Notes And Loans Payable Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Notes Payable Current | - | - | - | - | 1 | 1 | - | - | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 2 | 3 | 8 | 14 | 11 | 10 | 2 | 7 | 6 | 3 | 0 | 0 | ||||||
| Loans Payable Current | - | - | - | - | 0 | 0 | - | - | - | - | - | - | ||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 0 | - | - | - | - | - | ||||||
| Assets Held In Trust Noncurrent | - | - | - | - | - | - | 7 | 7 | 7 | 20 | 20 | 20 | ||||||
| Accrued Liabilities Current | 1 | 0 | 1 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Derivative Liabilities Current | - | - | 0 | 4 | - | - | - | - | - | - | - | - | ||||||
| Convertible Debt Current | - | - | 1 | 5 | 4 | 3 | - | - | - | - | - | - | ||||||
| Liabilities | 2 | 3 | 8 | 14 | 11 | 10 | 2 | 7 | 6 | 3 | 0 | 0 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 7 | 7 | 7 | 20 | 20 | 20 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital | 44 | 34 | 21 | 11 | 11 | 11 | 1 | 9 | 9 | 11 | 11 | 11 | ||||||
| Stockholders Equity | 12 | 4 | -6 | -11 | -10 | -8 | -2 | -1 | -1 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -32 | -30 | -27 | -23 | -21 | -19 | -3 | -15 | -15 | -14 | -11 | -11 | ||||||
| Liabilities And Stockholders Equity | 14 | 7 | 1 | 2 | 1 | 2 | 0 | 7 | 7 | 20 | 20 | 20 | ||||||
| Common Class A Subject To Redemption | - | - | - | - | - | - | - | 0 | 0 | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | 490 | 490 | 490 | 490 | 490 | 490 | 490 | - | - | - | - | - | ||||||
| Common Stock Shares Issued | 1 | 0 | 4 | 50 | 50 | 49 | 1 | - | - | - | - | - | ||||||
| Shares Outstanding | 1 | 0 | 4 | 50 | 50 | 49 | 1 | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAspire Biopharma Holdings, Inc. (ASBP) — SEC Financial Statements & Analysis
Aspire Biopharma Holdings, Inc. (ASBP) is a pharmaceutical preparations company, incorporated in E9. Aspire Biopharma Holdings, Inc. trades on Nasdaq as: ASBP, ASBPW. Aspire Biopharma Holdings, Inc. (ASBP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Aspire Biopharma Holdings, Inc. carries a market cap of $5.54M, a P/E ratio of -0.50x, a P/B ratio of 0.47x, a P/S ratio of 56.75x, an enterprise value of $-6.62M, and an EV/EBITDA multiple of 0.91x. On profitability, it posts a gross margin of -25.04%, an operating margin of -7494.76%, a net margin of -11314.12%, a Return on Equity (ROE) of -1032.14%, and a Return on Assets (ROA) of -152.09%. Per share, it reports EPS of $-10.65, diluted EPS of $-10.65, free cash flow per share of $-6.92, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -41.55% year-over-year and EPS growth of 2215.15% year-over-year. On the balance sheet, it maintains a current ratio of 7.99x, a quick ratio of 7.22x, working capital of $11.78M, a debt-to-equity ratio of 0.15x, a debt ratio of 0.13, an interest coverage ratio of -0.79x, free cash flow of $-7.19M (TTM), and net debt of $-12.17M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.54M
- P/E TTM
- -0.50x
- EPS TTM
- $-10.65
- P/B TTM
- 0.47x
- ROE TTM
- -1032.14%
- ROA TTM
- -152.09%
- Debt To Equity
- 0.15x
- Free Cash Flow TTM
- $-7.19M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Aspire Biopharma Holdings, Inc. in?
Aspire Biopharma Holdings, Inc. (ASBP) operates in the Pharmaceutical Preparations industry.
What exchange does ASBP trade on?
Aspire Biopharma Holdings, Inc. (ASBP) trades on the Nasdaq.
Where is Aspire Biopharma Holdings, Inc. incorporated?
Aspire Biopharma Holdings, Inc. is incorporated in Cayman Islands.
When was Aspire Biopharma Holdings, Inc. (ASBP)'s most recent SEC filing?
Aspire Biopharma Holdings, Inc. (ASBP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ASBP's market cap?
Aspire Biopharma Holdings, Inc. (ASBP) has a market capitalization of $5.54M as of 2026-06-30.
What is ASBP's EPS (earnings per share)?
Aspire Biopharma Holdings, Inc. (ASBP)'s trailing twelve month EPS is $-10.65 as of 2026-06-30.
What is ASBP's ROE (return on equity)?
Aspire Biopharma Holdings, Inc. (ASBP)'s trailing twelve month Return on Equity (ROE) is -1032.14% as of 2026-06-30.
What is ASBP's ROA (return on assets)?
Aspire Biopharma Holdings, Inc. (ASBP)'s trailing twelve month Return on Assets (ROA) is -152.09% as of 2026-06-30.
What is ASBP's EV/EBITDA?
Aspire Biopharma Holdings, Inc. (ASBP)'s trailing twelve month EV/EBITDA is 0.91x as of 2026-06-30.